The course of patients with Chagas heart disease during episodes of decompensated heart failure
- PMID: 33595916
- PMCID: PMC8006612
- DOI: 10.1002/ehf2.13232
The course of patients with Chagas heart disease during episodes of decompensated heart failure
Abstract
Aims: This study aimed to analyse the clinical presentation and prognosis of patients with Chagas cardiomyopathy and decompensated heart failure (HF), as compared with other aetiologies.
Methods and results: A prospective cohort of patients admitted with decompensated HF. We included 767 patients (63.9% male), with median age of 58 years [interquartile range 48.2-66.7 years]. Main aetiologies were non-Chagas/non-ischaemic cardiomyopathies in 389 (50.7%) patients, ischaemic disease in 209 (27.2%), and Chagas disease in 169 (22%). Median left ventricular ejection fraction was 26% (interquartile range 22-35%). Patients with Chagas differed from both patients with non-Chagas/non-ischaemic and ischaemic cardiomyopathies for a higher proportion of cardiogenic shock at admission (17.8%, 11.6%, and 11%, respectively, P < 0.001) and had lower blood pressure at admission (systolic blood pressure 90 [80-102.5], 100 [85-110], and 100 [88.2-120] mmHg, P < 0.001) and lower heart rate (heart rate 71 [60-80], 87 [70-102], and 79 [64-96.5] b.p.m., P < 0.001). Further, patients with Chagas had higher serum BNP level (1544 [734-3148], 1061 [465-239], and 927 [369-1455] pg/mL, P < 0.001), higher serum bilirubin (1.4 [0.922.44], 1.2 [0.77-2.19], and 0.84 [0.49-1.45] mg/dL, P < 0.001), larger left ventricular diameter (68 [63-73], 67 [58-74], and 62 [56.8-68.3] mm, respectively, P < 0.001), lower left ventricular ejection fraction (25 [21-30]%, 26 [22-35]%, and 30 [25-38]%, P < 0.001), and a higher proportion of patients with right ventricular function (48.8%, 40.7%, and 25.9%, P < 0.001). Patients with Chagas disease were more likely to receive inotropes than patients with non-Chagas/non-ischaemic and ischaemic cardiomyopathies (77.5%, 67.5%, and 62.5%, respectively, P = 0.007) and also to receive intra-aortic balloon pumping (30.8%, 16.2%, and 10.5%, P < 0.001). Overall, the rates of death or urgent transplant were higher among patients with Chagas than in other aetiologies, a difference that was driven mostly due to increased rate of heart transplant during hospital admission (20.2%, 10.3%, and 8.1%). The prognosis of patients at 180 days after hospital admission was worse for patients with Chagas disease as compared with other aetiologies. In patients with Chagas, age [odds ratio (OR) = 0.934, confidence interval (CI)95% 0.901-0.982, P = 0.005], right ventricular dysfunction by echocardiography (OR = 2.68, CI95% 1.055-6.81, P = 0.016), and urea (OR = 1.009, CI95% 1.001-1.018, P = 0.038) were significantly associated with prognosis.
Conclusions: Patients with Chagas cardiomyopathy and decompensated HF have a distinct clinical presentation and worse prognosis compared with other aetiologies.
Keywords: Chagas disease; Decompensated heart failure; Heart failure; Prognosis; Risk.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies.ESC Heart Fail. 2020 Oct;7(5):3086-3094. doi: 10.1002/ehf2.12936. Epub 2020 Aug 28. ESC Heart Fail. 2020. PMID: 32860353 Free PMC article.
-
Why do patients with chagasic cardiomyopathy have worse outcomes than those with non-chagasic cardiomyopathy?Arq Bras Cardiol. 2008 Dec;91(6):358-62. doi: 10.1590/s0066-782x2008001800006. Arq Bras Cardiol. 2008. PMID: 19142362
-
Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy.Open Heart. 2018 Dec 6;5(2):e000923. doi: 10.1136/openhrt-2018-000923. eCollection 2018. Open Heart. 2018. PMID: 30687507 Free PMC article.
-
Characterization of Patients With Heart Failure of Chagas Etiology in Colombia: An Analysis Based on the Colombian Registry of Heart Failure (RECOLFACA).Curr Probl Cardiol. 2023 Dec;48(12):101964. doi: 10.1016/j.cpcardiol.2023.101964. Epub 2023 Jul 19. Curr Probl Cardiol. 2023. PMID: 37473940 Review.
-
Co-occurrence of Myocardial Sarcoidosis and Left Ventricular Non-compaction in a Patient with Advanced Heart Failure.Card Fail Rev. 2022 Jun 20;8:e19. doi: 10.15420/cfr.2022.05. eCollection 2022 Jan. Card Fail Rev. 2022. PMID: 35795877 Free PMC article. Review.
Cited by
-
Chagas Cardiomyopathy and Myocardial Sympathetic Denervation.Curr Cardiol Rep. 2024 Jun;26(6):635-641. doi: 10.1007/s11886-024-02057-y. Epub 2024 Apr 24. Curr Cardiol Rep. 2024. PMID: 38656586 Review.
-
Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.Front Med (Lausanne). 2022 Jun 29;9:910388. doi: 10.3389/fmed.2022.910388. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35847824 Free PMC article. Review.
-
Cohort profile update: the main and new findings from the SaMi-Trop Chagas cohort.Rev Inst Med Trop Sao Paulo. 2021 Sep 27;63:e75. doi: 10.1590/S1678-9946202163075. eCollection 2021. Rev Inst Med Trop Sao Paulo. 2021. PMID: 34586309 Free PMC article.
-
Right-Sided Cardiac Thrombosis and Pulmonary Thromboembolism in Chronic Chagas Disease: A Review of Clinical Features and Post-Mortem Examination.Rev Cardiovasc Med. 2024 Jun 19;25(6):220. doi: 10.31083/j.rcm2506220. eCollection 2024 Jun. Rev Cardiovasc Med. 2024. PMID: 39076306 Free PMC article. Review.
-
Co-Exposure of Cardiomyocytes to IFN-γ and TNF-α Induces Mitochondrial Dysfunction and Nitro-Oxidative Stress: Implications for the Pathogenesis of Chronic Chagas Disease Cardiomyopathy.Front Immunol. 2021 Nov 11;12:755862. doi: 10.3389/fimmu.2021.755862. eCollection 2021. Front Immunol. 2021. PMID: 34867992 Free PMC article.
References
-
- World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015; 90: 33–43. PMID: 25671846. - PubMed
-
- Antinori S, Galimberti L, Grande R, Bianco R, Oreni L, Traversi L, Ricaboni D, Bestetti G, Lai A, Mileto D, Gismondo MR, Petullà M, Garelli S, de Maio G, Cogliati C, Torzillo D, Villa AM, Egidi AM, Repetto EC, Ridolfo AL, Corbellino M, Galli M. Chagas disease knocks on our door: a cross‐sectional study among Latin American immigrants in Milan. Italy Clin Microbiol Infect 2018; 24: 1340. - PubMed
-
- Bern C. Chagas' disease. N Engl J Med 2015; 373: 456–466. - PubMed
-
- Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol 2017; 70: 1510–1524. - PubMed
-
- Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV, PARADIGM‐HF and ATMOSPHERE Investigators and Committees . Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail 2017; 10: pii: e004361. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous